2025
Increased face perception in individuals at clinical high-risk for psychosis: mechanisms, sex differences, and clinical correlates
Tran T, Keane B, Thompson J, Robinson B, Kenney J, Williams T, Waltz J, Levin J, Kafadar E, Gold J, Schiffman J, Ellman L, Walker E, Strauss G, Mittal V, Zinbarg R, Corlett P, Powers A, Woods S, Silverstein S. Increased face perception in individuals at clinical high-risk for psychosis: mechanisms, sex differences, and clinical correlates. Schizophrenia 2025, 11: 74. PMID: 40355455, PMCID: PMC12069608, DOI: 10.1038/s41537-025-00624-y.Peer-Reviewed Original ResearchClinical high riskCHR participantsCHR groupPhase of psychotic illnessAssessment of psychosis riskSevere positive symptomsGender of facesAssess response biasClinical correlatesPositive symptomsPsychiatric controlsPsychosis riskPsychotic illnessAccuracy of perceptionFace perceptionScrambled conditionPerceptual sensitivityPoorer roleResponse biasFace testPerceptual organizationComputerized assessmentSex differencesAltered visual perceptionPsychosis
2023
The Acute Effects of Cannabinoids in Patients with Psychotic Illness
Ganesh S, Henquet C, Sewell R, Kuepper R, Ranganathan M, D’Souza D. The Acute Effects of Cannabinoids in Patients with Psychotic Illness. 2023, 225-239. DOI: 10.1017/9781108943246.023.Peer-Reviewed Original ResearchMental illnessMental health teamsHealth policy implicationsHigh-potency cannabisStages of neurodevelopmentPotential adverse effectsAcute effectsHealth teamsPsychotic illnessImpact of exposureCannabis dependenceAdverse effectsIllnessCannabisCannabinoidsSynthetic cannabinoidsPsychosisNew research findingsAssociationComplex associationPatientsNeurodevelopmentPutative modelSchizophreniaUsing dimensionality-reduction techniques to understand the organization of psychotic symptoms in persistent psychotic illness and first episode psychosis
Fleming L, Lemonde A, Benrimoh D, Gold J, Taylor J, Malla A, Joober R, Iyer S, Lepage M, Shah J, Corlett P. Using dimensionality-reduction techniques to understand the organization of psychotic symptoms in persistent psychotic illness and first episode psychosis. Scientific Reports 2023, 13: 4841. PMID: 36964175, PMCID: PMC10039017, DOI: 10.1038/s41598-023-31909-w.Peer-Reviewed Original ResearchConceptsHallucinations/delusionsFirst-episode psychosisFirst-episode psychosis participantsEarly intervention programsPathophysiological mechanismsUnderlying pathophysiologyEpisode psychosisPsychotic illnessPsychotic symptomsPsychotic disordersSchizoaffective disorderAuditory hallucinationsPositive symptomsHallucination severityNegative symptomsSymptomsDisorganization symptomsIntervention programsHallucinationsIllnessPsychosis participantsPsychosisDelusionsDisordersParticipantsEvaluation of boundaries between mood and psychosis disorder using dynamic functional network connectivity (dFNC) via deep learning classification
Rokham H, Falakshahi H, Fu Z, Pearlson G, Calhoun V. Evaluation of boundaries between mood and psychosis disorder using dynamic functional network connectivity (dFNC) via deep learning classification. Human Brain Mapping 2023, 44: 3180-3195. PMID: 36919656, PMCID: PMC10171526, DOI: 10.1002/hbm.26273.Peer-Reviewed Original ResearchConceptsDynamic functional network connectivityFunctional network connectivityDSM-IVFMRI-based measuresResting-state fMRI dataBiomarker-based approachPsychosis disordersClinical courseBipolar-Schizophrenia NetworkClinical evaluationSymptomatic measuresHealthy controlsPsychotic illnessHealthy individualsNeurological observationsMental disordersReliability of diagnosisStatistical group differencesMental healthNeuroimaging techniquesStatistical ManualDiagnostic problemsGroup differencesIntermediate phenotypesDisorders
2022
Folie en Famille: A Case Report of Shared Delusory Parasitosis
Al Siaghy A, Zoghbi Y, Azeem M. Folie en Famille: A Case Report of Shared Delusory Parasitosis. European Psychiatry 2022, 65: s779-s779. PMCID: PMC9567533, DOI: 10.1192/j.eurpsy.2022.2013.Peer-Reviewed Original ResearchDelusional parasitosisYear old femalePast psychiatric historyUnique therapeutic challengesPrimary patientsPruritic rashTherapeutic challengeCase reportMonths durationPsychiatric illnessMild symptomsMood disordersPsychotic illnessPsychotropic drugsPsychiatric historyPatient's husbandDelusional disorderDelusional symptomsBaby skinSecondary conditionsPartners of individualsPatientsSubstance useSomatic typePast historyTiming of cannabis exposure relative to prodrome and psychosis onset in a community-based first episode psychosis sample
Kline ER, Ferrara M, Li F, D'Souza DC, Keshavan M, Srihari VH. Timing of cannabis exposure relative to prodrome and psychosis onset in a community-based first episode psychosis sample. Journal Of Psychiatric Research 2022, 147: 248-253. PMID: 35066293, PMCID: PMC8882157, DOI: 10.1016/j.jpsychires.2022.01.039.Peer-Reviewed Original ResearchConceptsCannabis exposurePublic health significancePsychosis onsetPsychotic disordersHealth significanceFirst-episode psychosis samplePsychosis sampleFirst exposureFirst-episode psychosis servicesWorse premorbid functioningAdverse prognostic factorAssociation of ageImpact of cannabisPsychosis PreventionSymptom onsetPrognostic factorsOverall incidenceEarly psychosis sampleConsecutive admissionsOverall burdenPsychotic illnessPsychosis servicesPsychosis symptomsGreater severityYounger age
2020
The Effects of Augmenting Clozapine with Oxytocin in Schizophrenia: An Initial Case Series
Marotta RF, Buono FD, Garakani A, Collins E, Cerrito B, Rowe DR. The Effects of Augmenting Clozapine with Oxytocin in Schizophrenia: An Initial Case Series. Annals Of Clinical Psychiatry 2020, 32: 90-96. PMID: 32343282, DOI: 10.1177/104012372003200211.Peer-Reviewed Case Reports and Technical NotesConceptsTreatment-resistant schizophreniaNegative symptomsAtypical antipsychoticsRetrospective chart reviewInitial case seriesAugmentation of clozapineChronic psychotic illnessNegative Syndrome ScaleYoung adult inpatientsSymptoms of schizophreniaParent/guardian reportsChart reviewCase seriesAdult inpatientsProspective studyAntipsychotic medicationClinical reviewTherapeutic responsePsychotic illnessTreatment approachesSyndrome ScalePositive symptomsTreating psychiatristSymptomsSustained treatment
2018
17.2 EFFICACY OF CANNABIDIOL IN THE TREATMENT OF EARLY PSYCHOSIS.
Ranganathan M, D’Souza D, Cortes-Briones J, Skosnik P. 17.2 EFFICACY OF CANNABIDIOL IN THE TREATMENT OF EARLY PSYCHOSIS. Schizophrenia Bulletin 2018, 44: s27-s27. PMCID: PMC5887318, DOI: 10.1093/schbul/sby014.066.Peer-Reviewed Original ResearchEffects of cannabidiolEarly psychosisTreatment periodPsychotic symptomsFavorable side effect profileCritical treatment periodEfficacy of cannabidiolMedication side effectsSide effect profileAnti-psychotic effectsPhase of illnessWeeks of washoutTolerable medicationsCrossover studyEffect profileAntipsychotic medicationUntreated psychosisTraditional antipsychoticsEndocannabinoid systemMetabolic parametersPsychotic illnessElectrophysiological biomarkersSide effectsTreatment engagementPotential efficacy
2017
Inferring pathobiology from structural MRI in schizophrenia and bipolar disorder: Modeling head motion and neuroanatomical specificity
Yao N, Winkler AM, Barrett J, Book GA, Beetham T, Horseman R, Leach O, Hodgson K, Knowles EE, Mathias S, Stevens MC, Assaf M, van Erp TGM, Pearlson GD, Glahn DC. Inferring pathobiology from structural MRI in schizophrenia and bipolar disorder: Modeling head motion and neuroanatomical specificity. Human Brain Mapping 2017, 38: 3757-3770. PMID: 28480992, PMCID: PMC6867056, DOI: 10.1002/hbm.23612.Peer-Reviewed Original ResearchConceptsBipolar disorderStructural brain changesCortical thickness reductionsCortical thickness indexHealthy comparison subjectsHum Brain MappCortical thickness measurementsBrain changesLarge cohortNeuroanatomic abnormalitiesPsychotic illnessRegional specificityComparison subjectsFunctional changesSchizophreniaThickness indexCurrent imaging technologiesDisordersGroup structural differencesIllnessSimilar protocolEarlier reportsBiological factorsGroup effectsSpecificityExplaining Delusions: Reducing Uncertainty Through Basic and Computational Neuroscience
Feeney EJ, Groman SM, Taylor JR, Corlett PR. Explaining Delusions: Reducing Uncertainty Through Basic and Computational Neuroscience. Schizophrenia Bulletin 2017, 43: 263-272. PMID: 28177090, PMCID: PMC5605246, DOI: 10.1093/schbul/sbw194.Peer-Reviewed Original ResearchConceptsAssociative learning theoryPersistence of delusionsAttentional allocationCognitive psychologySet of beliefsAnimal beliefsNew learningComputational neuroscienceLearning theoryHuman beliefsErroneous beliefsBelief characteristicsBrain functionConsensual realityClinical phenomenologyAnimal researchBeliefsDelusionsComputational modelPsychotic illnessPsychologyPharmacological treatmentNeuroscienceTeleological approachFuture state
2015
First-Episode Services for Psychotic Disorders in the U.S. Public Sector: A Pragmatic Randomized Controlled Trial
Srihari VH, Tek C, Kucukgoncu S, Phutane VH, Breitborde NJ, Pollard J, Ozkan B, Saksa J, Walsh BC, Woods SW. First-Episode Services for Psychotic Disorders in the U.S. Public Sector: A Pragmatic Randomized Controlled Trial. Psychiatric Services 2015, 66: 705-712. PMID: 25639994, PMCID: PMC4490067, DOI: 10.1176/appi.ps.201400236.Peer-Reviewed Original ResearchConceptsUsual treatmentSTEP participantsCommunity mental health centerFirst-episode servicesFirst-episode psychosisMental health centersSerious mental illnessInpatient psychiatric unitAntipsychotic exposureAdditional patientsIllness onsetHospital utilizationHealth centersInpatient utilizationPsychiatric hospitalizationMAIN OUTCOMEPsychotic illnessPsychiatric unitPsychotic disordersHospitalizationEarly interventionMental illnessSpecialized treatmentPatientsTranslational research
2012
The neurobiology of schizotypy: Fronto-striatal prediction error signal correlates with delusion-like beliefs in healthy people
Corlett PR, Fletcher PC. The neurobiology of schizotypy: Fronto-striatal prediction error signal correlates with delusion-like beliefs in healthy people. Neuropsychologia 2012, 50: 3612-3620. PMID: 23079501, PMCID: PMC3694307, DOI: 10.1016/j.neuropsychologia.2012.09.045.Peer-Reviewed Original ResearchConceptsHealthy peopleSymptoms of psychosisPsychotic illnessEarly psychosisHealthy individualsPsychosis showHealthy beliefsAdditional alterationsNeural markersNeural responsesSymptomsPsychosisNovel evidenceDelusional ideationDistressSchizotypal experiencesAlterationsPatientsPrevious observationsIllness
2011
The acute effects of cannabinoids in patients with psychotic illness
Henquet C, Sewell A, Kuepper R, Ranganathan M, D’Souza D. The acute effects of cannabinoids in patients with psychotic illness. 2011, 198-209. DOI: 10.1017/cbo9780511706080.019.Peer-Reviewed Original ResearchMental health teamsImpact of cannabisEffects of cannabisPublic health specialistsCannabinoid systemAcute effectsHealth teamsPsychotic illnessHealth specialistsMental illnessMental healthEpidemiological factsCannabisIllnessAlcohol researchCannabis sativaNew research findingsPatientsSchizophreniaCannabinoids
2009
Review of the operational definition for first‐episode psychosis
Breitborde NJ, Srihari VH, Woods SW. Review of the operational definition for first‐episode psychosis. Early Intervention In Psychiatry 2009, 3: 259-265. PMID: 22642728, PMCID: PMC4451818, DOI: 10.1111/j.1751-7893.2009.00148.x.Peer-Reviewed Original ResearchConceptsFirst-episode psychosisDuration of psychosisEarly psychosis patientsAntipsychotic medication useFirst treatment contactRecent-onset psychosisMedication usePsychosis patientsTreatment contactPsychotic illnessClinical servicesPsychosisIllnessResearch settingsDurationOperational definitionTreatmentReviewPatientsSelective reviewIndividualsPublic-academic partnerships: early intervention for psychotic disorders in a community mental health center.
Srihari VH, Breitborde NJ, Pollard J, Tek C, Hyman L, Frisman LK, McGlashan TH, Jacobs S, Woods SW. Public-academic partnerships: early intervention for psychotic disorders in a community mental health center. Psychiatric Services 2009, 60: 1426-8. PMID: 19880454, PMCID: PMC4469899, DOI: 10.1176/appi.ps.60.11.1426.Peer-Reviewed Original ResearchConceptsMental health centersEarly interventionHealth centersConnecticut Mental Health CenterCommunity mental health centerLong-term outcomesEarly intervention servicesYounger patientsUntreated illnessPsychotic illnessPsychotic disordersAddiction servicesSpecialized treatmentMental healthInterventionConnecticut DepartmentIllnessPatientsPsychosisCannabis and psychosis/schizophrenia: human studies
D’Souza D, Sewell RA, Ranganathan M. Cannabis and psychosis/schizophrenia: human studies. European Archives Of Psychiatry And Clinical Neuroscience 2009, 259: 413-431. PMID: 19609589, PMCID: PMC2864503, DOI: 10.1007/s00406-009-0024-2.Peer-Reviewed Original ResearchConceptsPsychotic disordersRole of cannabinoidsPsychosis/schizophreniaTransient psychotic symptomsComponent causesCannabinoid receptor functionCauses of schizophreniaWarrants further studyDuration of exposureCannabinoid exposureTrigger relapsePsychotic illnessPsychotic symptomsGeneral populationCognitive symptomsHealthy individualsHuman studiesReceptor functionCannabis useNeurodevelopmental processesCannabinoidsFirst exposureSymptomsDisordersGenetic factorsCannabinoids and psychosis
Sewell RA, Ranganathan M, D'Souza DC. Cannabinoids and psychosis. International Review Of Psychiatry 2009, 21: 152-162. PMID: 19367509, DOI: 10.1080/09540260902782802.Peer-Reviewed Original ResearchConceptsGeneral populationPsychotic disordersTrigger relapseCannabis usersCognitive symptomsCross-sectional studyIndividual vulnerabilityCannabis useCannabinoid receptor functionLongitudinal studyCase seriesPsychotic illnessPsychotic symptomsCannabisHealthy individualsSchizophreniaPharmacological studiesReceptor functionAutobiographical accountsPsychosisEarly exposureSymptomsTwo-fold increaseConsiderable evidenceComponent causes
2004
Is the Party Over? Cannabis and Juvenile Psychiatric Disorder: The Past 10 Years
REY JM, MARTIN A, KRABMAN P. Is the Party Over? Cannabis and Juvenile Psychiatric Disorder: The Past 10 Years. Journal Of The American Academy Of Child & Adolescent Psychiatry 2004, 43: 1194-1205. PMID: 15381886, DOI: 10.1097/01.chi.0000135623.12843.60.Peer-Reviewed Original ResearchConceptsJuvenile psychiatric disordersPsychiatric disordersOnset of schizophreniaRole of cannabisMental health effectsRate of useRegular marijuana usePsychotic illnessDepressive symptomsRegular cannabisMental disordersSuicidal behaviorPsychosocial functioningLiterature databasesSystematic searchHealth effectsLate increaseCannabisDisordersAdolescent dataBehavioral problemsRecent dataMarijuana useCannabis researchEvidence points
1999
Symptom Assessment in Schizophrenic Prodromal States
Miller T, McGlashan T, Woods S, Stein K, Driesen N, Corcoran C, Hoffman R, Davidson L. Symptom Assessment in Schizophrenic Prodromal States. Psychiatric Quarterly 1999, 70: 273-287. PMID: 10587984, DOI: 10.1023/a:1022034115078.Peer-Reviewed Original ResearchConceptsProdromal symptomsEarly interventionLife-long illnessLong-term courseOnset of schizophreniaPublic health implicationsBetter prognosisSymptom assessmentAvailable treatmentsProdromal patientsPsychotic illnessProdromal stateProdromal stageSymptom severityNeurobiological deficitsIllnessHealth implicationsPatientsLong illnessSymptomsStructured interviewsSchizophreniaClinical workInterventionAssessment instruments
1998
Acute Neuroleptic Treatment in Elderly Patients Without Dementia
Mazure C, Nelson J, Jatlow P, Bowers M. Acute Neuroleptic Treatment in Elderly Patients Without Dementia. American Journal Of Geriatric Psychiatry 1998, 6: 221-229. PMID: 9659955, DOI: 10.1097/00019442-199800630-00005.Peer-Reviewed Original ResearchConceptsNon-elderly adultsElderly patientsNeuroleptic treatmentAcute responseLow dosesLow-dose neuroleptic treatmentAcute neuroleptic treatmentAdverse effectsHigh-dose treatmentLow-dose treatmentDrug blood levelsPrimary psychotic illnessInitial doseBlood levelsPsychotic illnessEffective treatmentPatientsDose ratioLonger durationTreatmentLower ratesDosesAdultsResponseNeuroleptics
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply